Chemotherapy Algorithm for Advanced Epithelial Ovarian Cancer Stage Ic–IV

**Consider entry into clinical trials for all eligible patients**

Tumour debulking**

*If ascites, pleural effusion or widespread peritoneal disease, start chemotherapy first (MDT decision), with surgery after 3 cycles*

---

Paclitaxel and Carboplatin* for patients with no contra-indication + Bevacizumab x 18 doses (if stage IV or sub-optimal debulking)

or

Carboplatin*

(for those not fit enough for doublet chemotherapy)

---

**BRCA1 or BRCA2 mutation, responded and progressed > 6 months later**

Paclitaxel + Carboplatin* or Caelyx + Carboplatin or Carboplatin*

---

Responded and progressed > 6 months later

Paclitaxel + Carboplatin* re-challenge or Carboplatin* or Caelyx + Carboplatin (if residual neuropathy only)

---

Responded and progressed > 12 months later

Platinum resistant

---

Caelyx + Carboplatin or Carboplatin*

---

Responded but progressed 6-12 months later

---

Progressive disease during chemotherapy, or < 6 months later

---

Progressive disease

---

**BRCA1 or BRCA2 mutation, responded and progressed > 6 months later**

Paclitaxel + Carboplatin* or Caelyx + Carboplatin or Carboplatin*

---

Responded and progressed > 12 months later

Paclitaxel + Carboplatin* or Caelyx + Carboplatin or Carboplatin*

---

Responded but progressed 6-12 months later

---

Progressive disease during chemotherapy, or < 6 months later

---

Progressive disease

---

Weekly Paclitaxel or Caelyx + Carboplatin (if not previously received) or Topotecan (only if progressed > 6 months after previous platinum treatment, i.e. platinum sensitive only) or Gemcitabine + Carboplatin* or Carboplatin*

(choice dependent on previous chemotherapy and toxicities, time to relapse and PS)

---

**Progression**

Use alternative: Caelyx or Weekly Paclitaxel

---

**Platinum resistant**

---

**PR / CR**

---

Olaparib maintenance

---

**Cisplatin may be substituted in patients with hypersensitivity reactions to carboplatin**

---

**Version: 8** Approved by Consultant Oncologist: Dr A Michael

Reason for Update: Caelyx & carboplatin added to 2nd line platinum-sensitive box, for those with residual neuropathy Approved by Consultant Oncologist: Dr S Essapen

Prepared by: S Taylor Date: 14.6.17